Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30839620 | 1.00 | PDE4A (0.44) | PDE4ATSHRCYP2C9LMNAALDH1A1 | |
| SCHEMBL28987639 | 1.00 | PDE4A (0.44) | PDE4ATSHRCYP2C9LMNAALDH1A1 | |
| SCHEMBL980780 | 0.87 | LMNA (0.31) | TSHRLMNAALDH1A1 | |
| SCHEMBL10477524 | 0.84 | TSHR (0.32) | TSHRALDH1A1 | |
| SCHEMBL11849643 | 0.78 | TSHR (0.35) | TSHRALDH1A1 | |
| Mucic Acid SCHEMBL5497 | 0.78 | TSHR (0.69) | PDE4ATSHRCYP2C9LMNAALDH1A1 | |
| Mucic Acid SCHEMBL17594183 | 0.78 | TSHR (0.69) | PDE4ATSHRCYP2C9LMNAALDH1A1 | |
| Mucic Acid SCHEMBL3514596 | 0.78 | TSHR (0.69) | PDE4ATSHRCYP2C9LMNAALDH1A1 | |
| Mucic Acid SCHEMBL7224759 | 0.78 | TSHR (0.69) | PDE4ATSHRCYP2C9LMNAALDH1A1 | |
| Mucic Acid SCHEMBL15895451 | 0.78 | TSHR (0.69) | PDE4ATSHRCYP2C9LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260110693-A1 | ASSAYS FOR LYSOSOMAL STORAGE DISEASES | SANGAMO THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4602369-A1 | ASSAYS FOR LYSOSOMAL STORAGE DISEASES | Sangamo Therapeutics, Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| WO-2024081868-A9 | ASSAYS FOR LYSOSOMAL STORAGE DISEASES | SANGAMO THERAPEUTICS, INC. (US) | 2025-02-06 | — | — | WO | disclosed |
| WO-2024081868-A1 | ASSAYS FOR LYSOSOMAL STORAGE DISEASES | SANGAMO THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| EP-3397270-B1 | COMPOSITIONS FOR USE IN THE TREATMENT OF HUNTER SYNDROME | GREEN CROSS CORP (KR) | 2024-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260110693-A1 | ASSAYS FOR LYSOSOMAL STORAGE DISEASES | GAA, GBA1, MAN2B1 | PDE4A 1958/4885TSHR 2908/4885CYP2C9 2983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.